An eight-week, multicenter, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of one fixed 100 mg dose of saredutant in patients with major depressive disorder.

Trial Profile

An eight-week, multicenter, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of one fixed 100 mg dose of saredutant in patients with major depressive disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2012

At a glance

  • Drugs Saredutant (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 16 Feb 2012 Actual patient number (460) added as reported by ClinicalTrials.gov.
    • 16 Feb 2012 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov.
    • 20 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top